{"id":"W2132784721","doi":"10.1136/gutjnl-2011-301668","title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","year":2012,"lang":"en","type":"article","venue":"Gut","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1495,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"Novartis Institutes for BioMedical Research; National Institutes of Health","keywords":"Secukinumab; Placebo; Medicine; Internal medicine; Clinical endpoint; Adverse effect; Crohn's disease; Confidence interval; Randomized controlled trial; Gastroenterology; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01367767,0.001073547,0.003609907,0.0003088164,0.0003779204,0.001129772,0.0006631245,0.002966248,0.00309785],"category_scores_gemma":[0.01205209,0.000506131,0.002951605,0.0004580441,0.001435002,0.0008370294,0.000340542,0.001788822,0.0004843022],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004666739,"about_ca_system_score_gemma":0.0008460125,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002618428,"about_ca_topic_score_gemma":0.000425405,"domain_scores_codex":[0.9949914,0.003300904,0.0006057723,0.0004487816,0.0004716419,0.0001815825],"domain_scores_gemma":[0.9918139,0.005294543,0.001511353,0.0004075521,0.0004324947,0.0005401964],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9458367,0.001405015,0.001330827,0.00406197,0.004849033,0.0001129818,0.00008792706,0.0002324612,0.005490617,0.0003280971,0.0009758695,0.03528849],"study_design_scores_gemma":[0.9505352,0.04041091,0.003199713,0.0002430665,0.002808461,0.00009278272,0.00001957093,0.0003434701,0.0006634241,0.0003049164,0.001357112,0.00002137],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8757789,0.09836024,0.005280617,0.00614482,0.004275856,0.005942904,0.001245896,0.0002301901,0.002740544],"genre_scores_gemma":[0.9705563,0.01587763,0.003207353,0.004044659,0.001823084,0.002605821,0.0005266337,0.00003244745,0.0013262],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01367767,"threshold_uncertainty_score":0.0723353,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02124235727899869,"score_gpt":0.3076641879383812,"score_spread":0.2864218306593825,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}